Chlorambucil-Induced Acute Interstitial Pneumonitis
Chlorambucil is an alkylating agent commonly used in treatment of chronic lymphocytic leukemia (CLL). We report a case of interstitial pneumonitis developing in an 83-year-old man 1.5 months after completing a six-month course of chlorambucil for CLL. The interstitial pneumonitis responded to therap...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Hindawi Publishing Corporation
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965935/ |
| id |
pubmed-3965935 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-39659352014-04-06 Chlorambucil-Induced Acute Interstitial Pneumonitis Shafqat, Hammad Olszewski, Adam J. Case Report Chlorambucil is an alkylating agent commonly used in treatment of chronic lymphocytic leukemia (CLL). We report a case of interstitial pneumonitis developing in an 83-year-old man 1.5 months after completing a six-month course of chlorambucil for CLL. The interstitial pneumonitis responded to therapy with prednisone. We performed a systematic review of literature and identified 13 other case reports of chlorambucil-induced pulmonary toxicity, particularly interstitial pneumonitis. No unifying risk factor could be discerned and the mechanism of injury remains unknown. In contrast, major randomized trials of chlorambucil therapy in CLL have not reported interstitial pneumonitis as an adverse effect, which may be due to the rarity of the phenomenon or due to underreporting of events occurring after completion of treatment. Clinicians should consider drug-induced interstitial pneumonitis in the differential diagnosis of a suggestive syndrome developing even after discontinuation of chlorambucil. Hindawi Publishing Corporation 2014 2014-02-12 /pmc/articles/PMC3965935/ /pubmed/24707414 http://dx.doi.org/10.1155/2014/575417 Text en Copyright © 2014 H. Shafqat and A. J. Olszewski. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Shafqat, Hammad Olszewski, Adam J. |
| spellingShingle |
Shafqat, Hammad Olszewski, Adam J. Chlorambucil-Induced Acute Interstitial Pneumonitis |
| author_facet |
Shafqat, Hammad Olszewski, Adam J. |
| author_sort |
Shafqat, Hammad |
| title |
Chlorambucil-Induced Acute Interstitial Pneumonitis |
| title_short |
Chlorambucil-Induced Acute Interstitial Pneumonitis |
| title_full |
Chlorambucil-Induced Acute Interstitial Pneumonitis |
| title_fullStr |
Chlorambucil-Induced Acute Interstitial Pneumonitis |
| title_full_unstemmed |
Chlorambucil-Induced Acute Interstitial Pneumonitis |
| title_sort |
chlorambucil-induced acute interstitial pneumonitis |
| description |
Chlorambucil is an alkylating agent commonly used in treatment of chronic lymphocytic leukemia (CLL). We report a case of interstitial pneumonitis developing in an 83-year-old man 1.5 months after completing a six-month course of chlorambucil for CLL. The interstitial pneumonitis responded to therapy with prednisone. We performed a systematic review of literature and identified 13 other case reports of chlorambucil-induced pulmonary toxicity, particularly interstitial pneumonitis. No unifying risk factor could be discerned and the mechanism of injury remains unknown. In contrast, major randomized trials of chlorambucil therapy in CLL have not reported interstitial pneumonitis as an adverse effect, which may be due to the rarity of the phenomenon or due to underreporting of events occurring after completion of treatment. Clinicians should consider drug-induced interstitial pneumonitis in the differential diagnosis of a suggestive syndrome developing even after discontinuation of chlorambucil. |
| publisher |
Hindawi Publishing Corporation |
| publishDate |
2014 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965935/ |
| _version_ |
1612071322632847360 |